β-Trcp and CK1δ-mediated degradation of LZTS2 activates PI3K/AKT signaling to drive tumorigenesis and metastasis in hepatocellular carcinoma

Yanwei Lu1 · Xudong Li1 · Hongli Liu1 · Jun Xue1 · Zhen Zeng1 · Xiaorong Dong1 · Tao Zhang1 · Gang Wu1 · Kunyu Yang1 · Shuangbing Xu1

Received: 23 June 2020 / Revised: 18 November 2020 / Accepted: 30 November 2020 / Published online: 8 January 2021
© The Author(s) 2020. This article is published with open access

Abstract
Distant metastasis is the leading cause of treatment failure in patients with hepatocellular carcinoma (HCC). However, the underlying mechanisms have not been fully elucidated. Here, we report that Leucine zipper tumor suppressor 2 (LZTS2) is downregulated and correlated with poor prognosis in HCC. Furthermore, we provide evidence that LZTS2 associates with p85 to inhibit the activation of PI3K/AKT signaling and impairs HCC tumorigenesis and metastasis in vitro and in vivo. Moreover, we identify LZTS2 as a bona fide substrate of the E3 ligase β-Trcp and protein kinase CK1δ, which are responsible for the ubiquitination and degradation of LZTS2. Importantly, we show that the β-Trcp and CK1δ-mediated degradation of LZTS2 promotes HCC progression and metastasis by activating PI3K/AKT signaling. Collectively, our study not only illustrates the roles of LZTS2 in regulating HCC tumorigenesis and metastasis but also reveals a novel posttranslational modification of LZTS2 by β-Trcp and CK1δ, indicating that the β-Trcp/CK1δ/LZTS2/PI3K axis may be a novel oncogenic driver involved in HCC progression and metastasis.

Introduction
Hepatocellular carcinoma (HCC), the most common histological type of primary liver cancer, is the third leading cause of cancer-related death worldwide [1]. At present, surgical resection, radiofrequency ablation, chemoembolization and personalized targeted therapy are beneficial for patients with HCC [2]. However, the overall prognosis of patients remains poor due to the high rate of postsurgical recurrence and distant metastasis [3]. Therefore, it is necessary to identify novel biomarkers and clarify the molecular mechanisms of tumor metastasis in HCC.

The ubiquitin-proteasome system (UPS) is the principal protein degradation machine that facilitates the proteasomal destruction of key regulatory proteins [4, 5]. This process consists of a cascade of three steps of enzymatic reactions, which are catalyzed by the ubiquitin-activating enzyme (E1), the ubiquitin-conjugating enzyme (E2) and the ubiquitin ligase enzyme (E3) [6, 7]. We previously found that the β-Trcp plays vital roles in cell cycle control, cell growth and apoptosis, angiogenesis, DNA damage repair and metabolism by recognizing specific substrates such as Wee1, BimEL, VEGFR2 and Set8 [13–16]. We previously found that the
tumor suppressor proteins FOXN2 and Mxi1 are ubiquitination substrates of the E3 ligase β-Trcp, and this ubiquitination modification is involved in lung cancer radioresistance [17, 18], supporting the role of β-Trcp in DNA damage repair.

Leucine zipper tumor suppressor 2 (LZTS2), also known as LAPSER1, is located on the 10q24.3 chromosomal region that is frequently deleted in various cancers [19]. Emerging evidence has implicated the roles of LZTS2 in development and tumorigenesis [20, 21]. For example, LZTS2 has been reported to suppress cell growth and proliferation in various cancer cell lines [22, 23]. Our previous study demonstrated that LZTS2 inhibits the expression of the PI3K/AKT signaling pathway to impair tumorigenesis and radioresistance in nasopharyngeal carcinoma [24]. These findings support the notion that LZTS2 acts as a tumor suppressor protein. In addition, LZTS2 was identified as a β-catenin-interacting protein and controlled the subcellular localization of β-catenin [25, 26], suggesting that LZTS2 might be associated with tumor metastasis. Nevertheless, the functions and underlying regulatory mechanisms of LZTS2 in metastasis remain to be clarified.

In this study, we present evidence that LZTS2 is downregulated and inhibits HCC progression and metastasis in vitro and in vivo. We further uncover that the E3 ubiquitin ligase β-Trcp and the protein kinase CK1δ-mediated destruction of LZTS2 contribute to tumorigenesis and metastasis by activating the PI3K/AKT signaling pathway in HCC. Our study reveals a previously unknown antitumorigenic role and a novel posttranslational modification of LZTS2, indicating that LZTS2 may be an attractive therapeutic target for HCC.

Results

LZTS2 is downregulated and inhibits HCC tumorigenesis in vitro and in vivo

To evaluate the clinical significance of LZTS2 in HCC, we first analyzed LZTS2 protein levels in five human HCC cell lines (SMMC-7721, MHCC-97H, HepG2, Huh7 and SK-Hep1). As shown in Fig. 1a, LZTS2 protein levels were significantly downregulated compared to that in the normal human liver cell line LO2. To further confirm whether LZTS2 expression was indeed downregulated, we verified the specificity of anti-LZTS2 antibody (Supplementary Fig. S1) and then performed IHC analysis of LZTS2 expression in a human HCC tissue microarray containing 86 carcinoma tissues and paired para-carcinoma tissues. As shown in Fig. 1b and c, LZTS2 positivity was significantly higher in the adjacent para-carcinoma tissues (66.3%) than in the HCC tissues (39.5%) (P < 0.001). Kaplan–Meier survival curve analysis demonstrated that HCC patients with low LZTS2 expression levels had a shorter overall survival than patients with high LZTS2 expression levels (P = 0.0043) (Fig. 1d), suggesting that low LZTS2 expression predicts poor prognosis in HCC. Given that LZTS2 expression is downregulated in HCC, we speculated that LZTS2 might act as a tumor suppressor in HCC. To test this hypothesis, we first depleted the expression of LZTS2 in two different HCC cell lines (SMMC-7721 and MHCC-97H) using siRNAs or shRNAs. As shown in Figs. 1e and 2a, the LZTS2 protein level was successfully knocked down. Our results showed that cell proliferation were markedly increased in LZTS2-deficient cells (Fig. 1f). Next, we wondered whether LZTS2 regulates tumorigenesis in vivo, a xenograft mouse model was established. As shown in Fig. 2b–e, both the tumor sizes and weights in the sh-LZTS2 groups was significantly increased than that in the sh-control group. Collectively, our data demonstrated that the loss of LZTS2 contributes to tumorigenesis in HCC.

LZTS2 depletion drives HCC metastasis in vitro and in vivo

Previous studies showed that LZTS2 binds to and controls the subcellular localization of β-catenin [25, 26], indicating that LZTS2 might be involved in tumor metastasis. To verify whether LZTS2 is associated with metastasis in HCC, we first detected the protein expression of epithelial-mesenchymal transformation-related markers and found that LZTS2 knockdown led to an elevation in Snail and Slug protein levels in two different HCC cell lines (Fig. 3a). In line with this idea, immunofluorescence staining further confirmed that greater Snail and Slug accumulation was observed in LZTS2-depleted cells (Fig. 3b). These results suggest that LZTS2 may play a key role in HCC metastasis. As expected, cell migration and invasion were dramatically increased in LZTS2-depleted cells (Fig. 3c and d), suggesting that LZTS2 inhibits HCC metastasis in vitro. To further investigate the in vivo effects of LZTS2 depletion on metastasis, an experimental lung metastasis model was employed to compare the metastatic nodules formed in the lungs of nude mice after inoculation with sh-control or sh-LZTS2 cells. As shown in Fig. 3e and f, the number of lung metastatic nodules was significantly increased in the mice injected with LZTS2-depleted cells. The results of these experiments support the notion that LZTS2 silencing drives HCC metastasis in vitro and in vivo.

LZTS2 inhibits the activation of the PI3K/AKT signaling pathway to impair HCC cell proliferation and metastasis in a p85-dependent manner

We previously demonstrated that LZTS2 binds to the PI3K subunit p85 to inhibit the activation of the PI3K/AKT
Given that PI3K/AKT activation is required for HCC progression and metastasis [27, 28], we wondered whether LZTS2 might be involved in these biological processes by modulating the PI3K/AKT pathway in HCC. To this end, we first investigated the association between LZTS2 and p85 in HCC. As shown in Fig. 4a, endogenous LZTS2 was capable of binding to endogenous p85 in two different HCC cell lines. It has been documented that the binding of PI3K subunit p85 to p110 is required for PI3K signaling activation. We surmised that LZTS2 may compete with p110 for p85 binding. As expected, overexpression of LZTS2 inhibited the binding of p85 to p110 (Fig. 4b). Moreover, we found that the level of phospho-AKT (p-AKT) was increased while total AKT, total p85 and phospho-p85 (p-p85) levels remained constant when LZTS2 was depleted (Fig. 4c). These findings demonstrate that LZTS2 binds to p85 and inhibits the activation of PI3K/AKT signaling in HCC. To investigate whether the participation of LZTS2 in HCC tumorigenesis and metastasis was dependent on the interaction between LZTS2 and p85, SMMC-7721 cells were transfected with siRNAs targeting LZTS2, p85 or both. As shown in Fig. 4d, LZTS2 silencing led to an increased accumulation of p-AKT. Nevertheless, the p-AKT level was unchanged when LZTS2 and p85 were simultaneously knocked down, suggesting that the activation of PI3K/AKT induced by LZTS2 depletion was dependent on p85. Notably, the loss of p85 led to the inhibition of cell growth, proliferation, migration and invasion (Fig. 4e–g), consistent with the notion that p85 is a critical regulatory subunit of PI3K. Importantly, we showed that the depletion of LZTS2 caused minimal effects on cell growth, proliferation, migration and invasion (Fig. 4e–g), consistent with the notion that p85 is a critical regulatory subunit of PI3K. Importantly, we showed that the depletion of LZTS2 caused minimal effects on cell growth, proliferation, migration and invasion (Fig. 4e–g), consistent with the notion that p85 is a critical regulatory subunit of PI3K.
However, the restoration of p85 partially reversed the effects of LZTS2 overexpression in HCC cells (Fig. 4e–g). Therefore, these results further support the idea that LZTS2 exerts its biological functions in a p85-dependent manner in HCC.

β-Trcp interacts with LZTS2 to control its protein stability

We previously conducted an unbiased tandem affinity purification (TAP) and mass spectrometry (MS) approach to identify LZTS2-binding proteins in HEK293T cells [24]. In addition to p85, we revealed that the E3 ligase β-Trcp is a candidate LZTS2-associated protein (Supplementary Fig. S2). To verify this interaction, a coimmunoprecipitation experiment was performed. As shown in Fig. 5a, exogenously expressed LZTS2 could bind to endogenous β-Trcp. We also observed an interaction between LZTS2 and β-Trcp at the endogenous level in SMMC-7721 and MHCC-97H cells (Fig. 5b). These results validate that β-Trcp is a LZTS2-interacting protein in HCC cells. Since β-Trcp is a well-known E3 ubiquitin ligase that controls the stability of the targeted protein, we surmised that LZTS2 might be a ubiquitination substrate of β-Trcp. As shown in Fig. 5c, β-Trcp knockdown using siRNAs targeting both β-Trcp1 and β-Trcp2 resulted in the accumulation of endogenous LZTS2 in three different HCC cell lines, suggesting that β-Trcp controls the stability of LZTS2. Moreover, treatment with the 26S proteasome inhibitor MG132 led to increased LZTS2 protein levels in HCC cells, implying that LZTS2 is a liable protein that can be degraded by the UPS (Fig. 5d). In addition, an in vivo ubiquitination assay revealed that the depletion of β-Trcp significantly reduced the polyubiquitination of LZTS2 (Fig. 5e). Consistent with these data, the half-life of exogenously expressed LZTS2 was markedly extended in β-Trcp-depleted cells. Overall, these data indicate that LZTS2 is a bona fide substrate of the β-Trcp ligase that targets it for ubiquitination and degradation.

CK1δ binds to and mediates the polyubiquitination and destruction of LZTS2

It has been well documented that the proper phosphorylation of substrates by one or a combination of specific kinase(s) is required for the recognition and binding by the E3 ligase β-Trcp [11]. To investigate the candidate kinases involved in the polyubiquitination and degradation of LZTS2 by β-Trcp, we first detected the interaction between LZTS2 and several protein kinases that have been reported to participate in priming β-Trcp phosphodegrons. As shown in Fig. 6a, no other kinases except CK1δ specifically bound to exogenously expressed LZTS2. In addition, the endogenous interaction between CK1δ and LZTS2 was also observed in three different HCC cell lines (Fig. 6b). These results demonstrated that CK1δ might be the specific
upstream kinase that triggers the ubiquitination and degradation of LZTS2 by β-Trcp. In line with this idea, knockdown of CK1δ led to decreased binding of LZTS2 to β-Trcp in HCC cells (Fig. 6c). To further confirm the potential role of CK1δ in regulating LZTS2 abundance, we depleted the expression of CK1δ using two different siRNAs and found...
that the loss of CK1δ led to an accumulation of LZTS2 (Fig. 6d). Moreover, the siRNA-mediated knockdown of CK1δ significantly reduced the polyubiquitination of LZTS2 (Fig. 6e). Consistent with the negative role of CK1δ in controlling LZTS2 stability, the depletion of endogenous CK1δ extended the half-life of exogenously expressed LZTS2 (Fig. 6f). Together, these results suggest that CK1δ is the upstream kinase that promotes the polyubiquitination and proteolysis of LZTS2 in HCC.

**The two conserved phosphodegrons in LZTS2 are responsible for the degradation of LZTS2 by β-Trcp and CK1δ**

It has been demonstrated that most β-Trcp substrates contain a conserved DSGXXS (X represents any amino acid) degron sequence that is critical for the recognition of β-Trcp [11], including β-Catenin, IκBα, Claspin and Emi1 (Fig. 7a). Unexpectedly, human LZTS2 contains two canonical DSGXXS degrons among various species (Fig. 7a). To investigate which degron when phosphorylated is required for governing LZTS2 stability, we mutated Ser220/Ser224 (LZTS2-M1) and/or Ser273/Ser277 (LZTS2-M2) to alanines to generate three phospho-deficient mutants. As shown in Fig. 7b, the single mutations of phosphodegron resulted in a decreased interaction between LZTS2 and β-Trcp. When both phosphodegrons of LZTS2 (LZTS2-M3) were mutated, it failed to associate with β-Trcp, showing that these two DSGXXS degrons are critical for the binding of LZTS2 and β-Trcp. Consistent with this finding, compared to wild-type LZTS2 (LZTS2-WT), a single mutation of each phosphodegron dramatically decreased the polyubiquitination of LZTS2, as detected by an in vivo ubiquitination assay (Fig. 7c). Notably, double mutations of phosphodegrons (LZTS2-M3) ablated the β-Trcp-mediated polyubiquitination of LZTS2 (Fig. 7c). Consistently, the half-life of the LZTS2-M3 mutant was markedly longer than that of LZTS2-WT (Fig. 7d). Taken together, these results demonstrate that these two phosphodegrons in LZTS2 are responsible for the β-Trcp ubiquitin ligase and CK1δ kinase-mediated ubiquitination and degradation of LZTS2.

**β-Trcp and CK1δ-mediated destruction of LZTS2 promotes cell proliferation and metastasis by activating PI3K/AKT signaling in HCC**

We have reported that LZTS2 participates in HCC progression and metastasis in a p85-dependent manner. Accordingly, we next explored the significance of LZTS2 ubiquitination modification in these biological processes in HCC. To this end, we reconstituted LZTS2-deficient cells with vectors expressing LZTS2-WT or the LZTS2-M3 mutant in the HCC cell line SMMC-7721. As shown in Fig. 8a, the ectopic expression of siRNA-resistant wild-type LZTS2 in LZTS2-deficient cells reduced the protein level of p-AKT, further supporting the negative role of LZTS2 in the regulation of PI3K/AKT signaling. Importantly, compared to the re-expression of LZTS2-WT, the restoration of the siRNA-resistant LZTS2 mutant resulted in a greater decrease in the level of p-AKT, indicating that the β-Trcp and CK1δ-mediated destruction of LZTS2 stimulates the activation of PI3K/AKT signaling in HCC. Notably, reconstitution with siRNA-resistant wild-type LZTS2 reversed the cell growth, proliferation, migration and invasion in LZTS2-depleted cells (Fig. 8b–e). These results support the roles of LZTS2 in HCC progression and metastasis. More importantly, the restoration of the siRNA-resistant LZTS2 mutant (LZTS2-M3), which is a mutant form that is nondegradable by β-Trcp and CK1δ, led to a greater inhibition of cell growth and proliferation compared to the expression of LZTS2-WT (Fig. 8b, c). Furthermore, LZTS2-M3 mutant restoration led to a smaller number of migrated and invaded cells than LZTS2-WT (Fig. 8d, e). Altogether, these findings reveal that the β-Trcp and CK1δ-mediated ubiquitination and degradation of LZTS2 drives HCC proliferation and metastasis by activating PI3K/AKT signaling.

**Discussion**

In this study, for the first time, we reveal the roles of LZTS2 in impairing tumorigenesis and metastasis in HCC in a p85-dependent manner. Moreover, we provided evidence that β-Trcp ubiquitin ligase and CK1δ protein kinase are responsible for the binding and subsequent ubiquitination of LZTS2. Clinically, LZTS2 is significantly downregulated, and a low level of LZTS2 is associated with poor clinical outcomes in HCC, implying that LZTS2 may act as a tumor suppressor and serve as a potential prognostic biomarker in HCC.
It has been demonstrated that LZTS2 could be regulated at the transcriptional level in different ways [29, 30]. For example, LZTS2 was a direct target of miR-300 involved in the self-renewal and differentiation of glioma stem-like cells [29]. In addition, LZTS2 promoter hypermethylation was observed and could be a potential prognostic biomarker in...
LZTS2 silencing activates the PI3K/AKT signaling pathway to promote HCC progression and metastasis in a p85-dependent manner. a SMMC-7721 and MHCC-97H cells were collected and subjected to immunoprecipitation (IP) using an anti-IgG or anti-LZTS2 antibody and then analyzed by western blotting (n = 3). b SMMC-7721 and MHCC-97H cells were transfected with indicated plasmids for 24 h. Immunoprecipitation was performed with Myc beads, and western blotting was carried out with the indicated antibodies (n = 3). c LZTS2 deficiency increased the protein level of p-AKT in SMMC-7721 and MHCC-97H cells (n = 3). d SMMC-7721 cells were transfected with the indicated siRNAs. Forty-eight hours later, the cells were harvested and analyzed by western blotting (n = 3). e SMMC-7721 cells were transfected with the indicated siRNAs or plasmids. The cell numbers were calculated every other day. The results are presented as the mean ± SD. ***P < 0.001 (n = 3). f SMMC-7721 cells transfected with the indicated siRNAs or plasmids were grown for two weeks. The colonies were examined, and the results are shown with histograms (upper panel). Representative violet staining images are shown (lower panel). n.s. indicates no statistically significant difference (P > 0.05), ***P < 0.001 (n = 3). g SMMC-7721 cell migration (upper panel) and invasion (lower panel) were determined using transwell assays. ***P < 0.001 (n = 3).

LZTS2 is a new physiological substrate of the β-Trcp, further supporting the idea that LZTS2 may function as a tumor suppressor in HCC. Mechanistic studies revealed that LZTS2 inhibits the activation of PI3K/AKT signaling to participate in carcinogenesis by interacting with p85, which is the most prevalent regulatory subunit of the heterodimeric enzyme PI3K. In addition, we uncovered a novel role of LZTS2 in suppressing HCC metastasis. Our results showed that LZTS2-depleted HCC cells displayed enhanced metastatic potential in vitro and in vivo and had an increased expression of Snail and Slug. Notably, the levels of nuclear/cytoplasmic localization of β-Catenin were not changed following LZTS2 suppression in HCC cells (Supplementary Fig. S3), indicating that β-Catenin is not involved in LZTS2-mediated HCC metastasis. It has been well established that the PI3K/AKT pathway is frequently activated and associated with metastasis in HCC [27, 28]. Therefore, our data indicate that LZTS2 silencing activates PI3K/AKT signaling, subsequently driving HCC metastasis. More importantly, our rescue experiments illustrated that the LZTS2 mutant was more potent than wild-type LZTS2 in inhibiting the activation of PI3K/AKT signaling and impairing cell proliferation and metastasis, suggesting that β-Trcp and CK1δ-mediated LZTS2 degradation promotes tumorigenesis and metastasis by activating PI3K/AKT signaling in HCC.

In conclusion, our findings demonstrated that the ubiquitin ligase β-Trcp and protein kinase CK1δ are crucial upstream modulators that control the stability of LZTS2 and reveal that the PI3K/AKT signaling pathway is the main downstream effector involved in LZTS2-mediated biological processes, as proposed in Fig. 8f. Our results not only provide new insights into the molecular mechanisms by which LZTS2 is controlled but also offer a potential therapeutic strategy for HCC.

Materials and methods

Cell culture

Five hepatocellular carcinoma (HCC) cell lines (MHCC-97H, SMMC-7721, HepG2, Huh7 and SK-Hep1), LO2, HeLa and HEK293T were obtained from the American Type Culture Collection (ATCC) and maintained in Dulbecco’s modified essential medium (DMEM) containing 10% fetal bovine serum (FBS) and 100 μg/mL penicillin and streptomycin with 5% CO2 at 37 °C.

Plasmids

The pDOR-LZTS2 vector was purchased from DF/HCC DNA Resource Core. The Myc-β-Trcp plasmid was kindly provided by Dr. Wenyi Wei (Harvard Medical School, USA). The pDOR-LZTS2 vector was transferred to the Gateway compatible
destination vector with the indicated SFB, Myc and HA tags using Gateway Technology (Invitrogen). Mutations were conducted using the KOD Hot Start Kit (Novagen), followed by DNA sequencing validation. Plasmids were transfected using polyethylenimine reagent or Lipofectamine 2000 (Invitrogen).

**Antibodies and reagents**

Human anti-LZTS2 antibodies were obtained from Proteintech (15677-1-AP) (for western blotting) and Bethyl (A304-938A-T) (for IP). Human anti-β-Trcp (#4394), anti-HA (#3724), anti-phospho-AKT (#4060), anti-AKT (#4685), anti-p85 (#4257), anti-p110 (#3011), anti-CK1ε (#12448), anti-Snail (#3879), anti-Slug (#9585), anti-N-Cadherin (#13116), anti-E-Cadherin (#3195), anti-ZO-1 (#8480), anti-β-Catenin (#85741), anti-TCP8 (#3396), and anti-Claudin-1 (#13255) antibodies were obtained from Cell Signaling Technology. Human anti-S6K1 (sc-8418), anti-GAPDH (sc-47724) and anti-Myc (sc-40) antibodies were purchased from Santa Cruz Biotechnology.

**Fig. 5 β-Trcp interacts with LZTS2 and triggers the ubiquitination and degradation of LZTS2.**

a SMMC-7721 and MHCC-97H cells were transfected with the indicated plasmids. IP experiments were performed using S-protein beads and blotted with the indicated antibodies (n = 3). b The endogenous interaction between LZTS2 and β-Trcp was detected in HCC cells. IgG was used as a negative control (n = 3). c β-Trcp silencing led to the accumulation of endogenous LZTS2 in different HCC cells (n = 3). d HCC cells were treated with or without MG132 for 4 h, and the protein expression of endogenous LZTS2 was determined by western blotting (n = 3). e HeLa cells were transfected with siRNAs or plasmids as indicated. The cells were treated with MG132 (10 μM) for 4 h before harvesting. The lysates were incubated with Myc beads and then subjected to immunoblotting to examine the ubiquitination of exogenous LZTS2 (n = 3). WCL: whole cell lysates. f Upper panel: HeLa cells transfected with the indicated siRNAs or plasmids were treated with 20 μg/mL cycloheximide (CHX) and harvested at the indicated time points. Western blotting was conducted to detect the protein level of LZTS2. Lower panel: quantification of the exogenously expressed LZTS2 band intensity is shown. ***P < 0.001 (n = 3).
Fig. 6 CK1δ binds to LZTS2 and negatively controls the stability of LZTS2. a SMMC-7721 and HeLa cells were transfected with the indicated plasmid, followed by IP with S-protein beads and western blotting with the indicated antibodies \((n = 3)\). b Endogenous CK1δ associated with LZTS2 in HCC cells. The cells were lysed and subjected to IP using an anti-IgG or anti-LZTS2 antibody and then analyzed by western blotting using the indicated antibodies \((n = 3)\). c Knockdown of CK1δ led to decreased binding of LZTS2 to β-Trcp \((n = 3)\). SMMC-7721 and MHCC-97H cells were transfected with the indicated siRNAs and plasmids, followed by treatment with MG132 \((10 \, \mu M)\) for 4 h prior to collection. d CK1δ depletion increased the endogenous protein levels of LZTS2 in SMMC-7721 and HeLa cells \((n = 3)\). e Knockdown of CK1δ impairs the ubiquitination of LZTS2 in vivo. HeLa cells were transfected with the indicated siRNAs and plasmids, followed by treatment with MG132 \((10 \, \mu M)\) for 4 h prior to collection. The lysates were incubated with S-protein beads and then subjected to western blotting \((n = 3)\). f Upper panel: knockdown of CK1δ prolonged the half-life of LZTS2 in HeLa cells. Lower panel: quantification of the exogenously expressed LZTS2 band intensity is shown. *** \(P < 0.001\) \((n = 3)\).
and anti-Lamin B1 (A11495) antibody were obtained from ABclonal Technology. Anti-phospho-p85 antibody (AF5905) was purchased from Beyotime Biotechnology. Cycloheximide (CHX, A8244) and MG132 (474790) were purchased from Sigma-Aldrich and Millipore, respectively.

**RNA interference**

siRNA transfection was carried out using RNAiMAX transfection reagent (Invitrogen) according to the manufacturer’s instructions. Transfected cells were cultured for 48 h before use. To construct the LZTS2 siRNA-resistant plasmid, seven nucleotide substitutions were introduced into the LZTS2 siRNAs target sequence. The following target siRNA sequences were used in this study:

- **β-Trcp** siRNA: 5’-AAGUGGAUUUGUGGAACAUC-3’
- **LZTS2** siRNA-1: 5’-GGAGGAGAUCACGUAUCU-3’
- **LZTS2** siRNA-2: 5’-GUGUGAGCAGCUUAUCUC-3’
- **CK1δ** siRNA-1: 5’-UGAUCAUCCGGAUCGGAUU-3’
- **CK1δ** siRNA-2: 5’-GGUCUAGGAUCGAAUGUU-3’

**Establishment of stable cell lines**

HEK293T cells were transfected with the indicated shRNAs and the packaging plasmids pSPAX2 and pMD2G. Forty-eight hours after transfection, lentiviral supernatants were collected with a 0.45 mm filter and then used to infect MHCC-97H cells in the presence of 10 μg/mL Polybrene (Sigma, St. Louis, MO, USA). Stable cell lines were selected with media containing 2 μg/mL puromycin and confirmed by western blotting. The shRNA sequences were as follows:

- **Control shRNA**: 5’-TCTCGCTTGGGCGAGAGTAAG-3’
- **LZTS2** shRNA-1: 5’-TGATGTAGAGCCGTGCTTG-3’
- **LZTS2** shRNA-2: 5’-TGACGGGTCTTGATCGCT-3’

**Western blotting and immunoprecipitation**

Cell lysates were prepared using NETN buffer (20 mM Tris HCl (pH 8.0), 100 mM NaCl, 1 mM EDTA, and 0.5% Nonidet P-40) on ice for 30 min, separated by SDS-PAGE.
and then transferred to PVDF membranes for western blotting using ECL detection reagents. For exogenous immunoprecipitation, the samples were incubated with S-protein beads (Millipore) or anti-Myc agarose (Santa Cruz Biotechnology) overnight at 4 °C. For endogenous binding, the supernatants were incubated with anti-LZTS2 for 2 h and protein A/G-agarose overnight. The precipitates were washed five times using NETN buffer and analyzed by western blotting.

**In vivo ubiquitination assay**

Cells were co-transfected with the indicated siRNAs and plasmids and lysed using NETN buffer solution with the
addition of MG132 (10 μM) 4 h prior to collection. The lysates were incubated with S protein beads overnight at 4 °C. After being washed five times with NETN buffer, the beads were boiled and the pull-down proteins were resolved by SDS-PAGE.

**Protein degradation assay**

The cells were transfected with the indicated siRNAs and plasmids. Alternatively, the cells were directly transfected with HA-tagged LZTS2-WT (wild-type) or LZTS2-M3 (mutant) plasmids. After transfection, 20 μg/mL CHX was added to the medium at the indicated times. The protein levels were detected by western blotting.

**Cell growth and colony formation assays**

After transfection with the indicated siRNAs or plasmids, the cells were seeded into six-well plates at 1 × 10⁴ cells/well, and cell numbers were counted every other day. For the colony formation assay, transfected cells were seeded into six-well plates at 1 × 10⁴ cells/well, and cell numbers were counted every other day. For the colony formation assay, transfected cells were seeded in a six-well plate at a density of 500 cells/well and then cultured for 2 weeks. After fixation and staining, the number of colonies (more than 50 cells) was calculated.

**EdU assay**

Cell proliferation was measured by the 5-ethynyl-2-deoxyuridine (EdU) Assay Kit (RiboBio, Guangzhou, China). The cells were plated at a density of 3 × 10⁵ cells/well in 96-well plates and incubated with 50 μM EdU for 2 h at 37 °C. After fixation with 4% formaldehyde and permeabilization with 0.5% Triton X-100, the cells were treated with 100 μL of 1×Apollo® reaction cocktail for 30 min. Subsequently, the nuclei of the cells were stained with 100 μL of DAPI for 30 min. The cells were visualized and photographed under a fluorescence microscope.

**Immunofluorescence staining**

SMMC-7721 or MHCC-97H cells were transfected with the indicated siRNAs and seeded on coverslips. After being fixed, the cells were blocked with 5% bovine serum albumin and then incubated with anti-Snail and anti-Slug antibodies overnight. The samples were incubated with the secondary antibody for 1 h and then counterstained with DAPI for 10 min and visualized using a fluorescence microscope.

**Cell migration and invasion assays**

These assays were performed as described previously [34, 35]. In brief, the migration assay was performed using a 24-well transwell plate in which 4 × 10⁴ cells in 200 μL of serum-free Dulbecco’s modified essential medium (DMEM) were added to the upper chamber. For the invasion assay, 1 × 10⁵ cells in 200 μL of serum-free DMEM were plated in the upper chambers of the transwell plates with Matrigel-coated membranes. The cells were allowed to migrate or invade for 24 h toward the lower chambers with 10% fetal bovine serum (FBS) media, and then they were fixed and stained with crystal violet. The stained cells were photographed and counted.

**In vivo mouse models**

All animal experiments were approved by the Medical Ethics Committee of Tongji Medical College, Huazhong University of Science and Technology. BALB/c nude mice (5-6 weeks old) were randomly divided into three groups consisting of five mice each and subcutaneously injected with 5 × 10⁶ MHCC-97H stable cells (sh-Control and sh-LZTS2). Tumor growth was measured by a blinded reader with callipers every four days, and tumor volumes were calculated according to the formula \( V = (L \times W^2)/2 \), where \( V \) = volume (mm³), \( L \) = length (mm), and \( W \) = width (mm). For the tail vein lung metastasis model, the mice were intravenously injected with 3 × 10⁵ MHCC-97H stable cells (sh-Control and sh-LZTS2) in 150 μL of phosphate-buffered saline (PBS) through the tail vein. After 8 weeks, the mice were sacrificed, and all lung tissues were collected, fixed and sectioned, followed by haematoxylin and eosin staining. Macroscopic metastases were quantified by counting lesions in all five lobes of the lung per mouse.
Tissue microarray and immunohistochemical (IHC) staining

An HCC tissue microarray, which contained 86 carcinoma tissues and paired para-carcinoma tissues, was obtained from Shanghai Outdo Biotech (Shanghai, China). All patients were pathologically diagnosed with HCC. IHC analysis was performed as previously described [35–37]. In brief, tissue sections were blocked with goat serum and then incubated with an anti-LZTS2 antibody (HPA044956, Sigma-Aldrich) overnight at 4°C. The slides were incubated with the secondary antibody and reacted with 3,3-diaminobenzidine, followed by counterstaining with hematoxylin. Both the percentage of positive areas (0–25% = 1, 26–50% = 2, 51–75% = 3, >75% = 4) and immunostaining intensity (negative = 0, weak = 1, moderate = 2, or strong = 3) were recorded to evaluate the expression of LZTS2. The total score (values 0–12) was calculated by multiplying these two values. The score equal to or higher than six was defined as high expression, while the score less than six was defined as low expression.

Statistical analysis

Individual experiments were repeated independently three or more times. The data were analyzed using GraphPad Prism V6.0 and are presented as the mean ± SD unless otherwise stated. Statistical significance was analyzed using Student’s t test (unpaired, two-tailed). Kaplan–Meier survival analysis was performed to illustrate the prognostic value of LZTS2 in HCC patients. A P value < 0.05 was considered statistically significant.

Acknowledgements

This work was supported by the Hubei Provincial Natural Science Fund for Distinguished Young Scholars (2019CFA063 to SX), the National Natural Science Foundation of China (81874041 to SX), and the grants from the Wuhan Science and Technology Bureau (2019020701011437 to SX).

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34.
2. Former A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391:1301–14.
3. Asrani SK, Devabhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019;70:151–71.
4. Nakayama KI, Nakayama K. Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer. 2006;6:369–81.
5. Yau R, Rafe M. The increasing complexity of the ubiquitin code. Nat Cell Biol. 2016;18:579–86.
6. Komander D, Rafe M. The ubiquitin code. Annu Rev Biochem. 2012;81:203–29.
7. Senft D, Qi J, Ronai ZA. Ubiquitin ligases in oncogenic transformation and cancer therapy. Nat Rev Cancer. 2018;18:69–88.
8. Skara JR, Pagan JK, Pagano M. Mechanisms and function of substrate recruitment by F-box proteins. Nat Rev Mol Cell Biol. 2013;14:369–81.
9. Zheng N, Wang Z, Wei W. Ubiquitination-mediated degradation of cell cycle-related proteins by F-box proteins. Int J Biochem Cell Biol. 2016;73:99–110.
10. Bu etow L, Huang DT. Structural insights into the catalysis and regulation of E3 ubiquitin ligases. Nat Rev Mol Cell Biol. 2016;17:626–42.
11. Frescas D, Pagano M. Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat Rev Cancer. 2008;8:438–49.
12. Zheng N, Zhou Q, Wang Z, Wei W. Recent advances in SCF ubiquitin ligase complex: clinical implications. Biochim Biophys Acta. 2016;1866:12–22.
13. Watanabe N, Arai H, Nishihara Y, Taniguchi M, Watanabe N, Hunter T, et al. M-phase kinases induce phospho-dependent ubiquitination of somatic Weel by SCFbeta-TrCP. Proc Natl Acad Sci USA. 2004;101:4419–24.
14. Debar E, Bassermann F, Guardavaccaro D, Vasiliver-Shamis G, Cohen M, Lowes KN, et al. beta-TrCP- and Rsk1/2-mediated degradation of BimEL inhibits apoptosis. Mol Cell. 2009;33:109–16.
15. Shai K, Nucera C, Inuzuka H, Gao D, Gararna M, Frechette G, et al. SCF(beta-TrCP) suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2. J Exp Med. 2012;209:1289–307.
16. Wang Z, Dai X, Zhong J, Inuzuka H, Wan L, Li X, et al. SCF (beta-TrCP) promotes cell growth by targeting PR-Set7/Set8 for degradation. Nat Commun. 2015;6:10185.
17. Ma J, Lu Y, Zhang S, Li Y, Huang J, Yin Z, et al. beta-Trcp ubiquitin ligase and RSK2 kinase-mediated degradation of FOXN2 promotes tumorigenesis and radioresistance in lung cancer. Cell Death Differ. 2018;25:1473–85.
18. Huang Y, Hu K, Zhang S, Dong X, Yin Z, Meng R, et al. S6K1 phosphorylation-dependent degradation of Mxi1 by beta-Trcp ubiquitin ligase promotes Myc activation and radioresistance in lung cancer. Thernanostics. 2018;8:1286–300.
19. Cabez a-Arvelaiz Y, Thompson TC, Sepulveda JL, Chiu nalt AC. LAPSER1: a novel candidate tumor suppressor gene from 1q42.43. Oncogene. 2001;20:6707–17.
20. Johnson DT, Luong R, Lee SH, Peng Y, Shaltouki A, Lee JT, et al. Deletion of leucine zipper tumor suppressor 2 (Lzts2)
increases susceptibility to tumor development. J Biol Chem. 2013;288:3727–38.

21. Peng Y, Clark C, Luong R, Tu WH, Lee J, Johnson DT, et al. The leucine zipper putative tumor suppressor 2 protein LZTS2 regulates kidney development. J Biol Chem. 2011;286:40331–42.

22. Kim JM, Song JS, Cho HH, Shin KK, Bae YC, Lee BJ, et al. Effect of the modulation of leucine zipper tumor suppressor 2 expression on proliferation of various cancer cells functions as a tumor suppressor. Mol Cell Biochem. 2011;346:125–36.

23. Cui QZ, Tang ZP, Zhang XP, Zhao HY, Dong QZ, Xu K, et al. Leucine zipper tumor suppressor 2 protein LZTS2 regulates kidney development. J Biol Chem. 2011;286:40331–42.

24. Xu S, Li Y, Lu Y, Huang J, Ren J, Zhang S, et al. LZTS2 inhibits PI3K/AKT activation and radioresistance in nasopharyngeal carcinoma by interacting with p85. Cancer Lett. 2018;420:38–48.

25. Thyssen G, Li TH, Lehmann L, Zhuo M, Sharma M, Sun Z. LZTS2 is a novel beta-catenin-interacting protein and regulates the nuclear export of beta-catenin. J Histochem Cytochem. 2013;61:659–70.

26. Xu S, Li Y, Lu Y, Huang J, Ren J, Zhang S, et al. LZTS2 inhibits PI3K/AKT activation and radioresistance in nasopharyngeal carcinoma by interacting with p85. Cancer Lett. 2018;420:38–48.

27. Lu Y, Ma J, Li Y, Huang J, Zhang S, Yin Z, et al. CDK16 phosphorylates and degrades p53 to promote radioresistance and predicts prognosis in lung cancer. Theranostics. 2018;8:650–62.